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Rationale: Therapeutic exercise training has been shown to significantly improve
pulmonary hypertension (PH), including 6-min walking distance and right heart function.
Supplemental nightly oxygen also has therapeutic effects. A biomarker tool that could
query critical gene networks would aid in understanding the molecular effects of the
interventions.
Methods: Paired bio-banked serum (n = 31) or plasma (n = 21) samples from the
exercise or oxygen intervention studies, respectively, and bio-banked plasma samples
(n = 20) from high altitude induced PH in cattle were tested. MicroRNAs (miRNAs)
markers were chosen for study because they regulate gene expression, control the
function of specific gene networks, and are conserved across species.
Results: miRNAs that control muscle (miR-22-3p, miR-21-5p) or erythrocyte function
(miR-451a) were chosen based on pilot experiments. Plasma samples from cattle that
developed PH in high altitude had significantly higher miR-22-3p/(relative to) miR-451a
values when compared to control cattle tolerant to high altitude. Measurements of miR-
22-3p/miR-451a values in serum from patients receiving exercise training showed that
the values were significantly decreased in 74.2% of the samples following intervention
and significantly increased in the remainder (25.8%). In samples obtained after exercise
intervention, a higher composite miRNA value, made of miR-22-3p and miR-21-5p/miR-
451a and spike RNA, was significantly decreased in 65% of the samples and significantly
increased in 35% of the samples. In the study of nightly oxygen intervention, when
comparing placebo and oxygen, half of the samples showed a significant down-ward
change and the other half a significant up-ward change measuring either of the miRNA
markers. Samples that had a downward change in the miRNA marker following either
intervention originated from patients who had a significantly higher 6-min-walking-
distance at baseline (mean difference of 90 m or 80 m following exercise or oxygen
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intervention, respectively) when compared to samples that had an upward change in
the miRNA marker.
Conclusion: These natural animal model and human sample studies further highlight
the utility of miRNAs as future biomarkers. The different directional changes of the
miRNA markers following supervised exercise training or nightly oxygen intervention
could indicate different PAH molecular pathomechanisms (endotypes). Further studies
are needed to test this idea.
Keywords: pulmonary hypertension, MicroRNA, circulating biomarker, high altitude pulmonary hypertension,
supervised exercise training, nightly oxygen intervention
INTRODUCTION
Pulmonary hypertension (PH) is a progressive disease for which
there is no cure. PH is characterized by increased blood pressure
in the pulmonary vasculature and the right heart, and can occur
as a primarily vascular disease, or associated with conditions
that cause pulmonary vascular remodeling and constriction. In
all instances, PH leads to adverse clinical outcomes relative to
the respective disease or healthy control groups that have no
PH, and can be the cause of early mortality with 2–5 years
life expectancy. The current World Symposium on Pulmonary
Hypertension (WSPH) classification of PH is based on a
combination of patient characteristics, clinical features and
cardiopulmonary hemodynamics and these WHO groups are
used to inform drug treatment options (Simonneau et al., 2013).
Recently, PH interventions based on supervised exercise training
and nightly oxygen have been developed that have significant
therapeutic effect to a degree that is expected from adding
another drug for multi-drug treatment of PH (Mereles et al.,
2006; Grunig et al., 2011, 2012a,b; Nagel et al., 2012; Becker-
Grunig et al., 2013; Schumacher et al., 2014; Pandey et al.,
2015; Ulrich et al., 2015; Ehlken et al., 2016; Gonzalez-Saiz et al.,
2017; Keusch et al., 2017; Moreira-Goncalves et al., 2017; Richter
et al., 2017; Leggio et al., 2018). Already after a 3-week period,
supervised exercise training improved, for example, the 6MWD
and hemodynamics, which are important signs for PH prognosis
(Grunig et al., 2012a,b). Nightly oxygen, even after 1 week,
likewise, significantly improved the 6MWD (Schumacher et al.,
2014; Ulrich et al., 2015).
Aside from genetic testing and the measurement of the
right-heart stress markers B-type natriuretic peptide biomarkers
that would identify the molecular or cellular pathobiologic
mechanism that identify the cause of PH are not established
(Hoffmann et al., 2016). Further, biomarkers that could explain
the effects of therapeutic interventions like supervised exercise
training or nightly oxygen, would aid in the understanding of
the causes of PH, and represent optimal monitoring tools for the
disease. Additionally, biomarkers that could identify underlying
molecular mechanisms would be important to understand
the diversity of PH by characterizing subtypes of PH that
are distinguished by molecular pathomechanisms [endotypes
Abbreviations: 6MWD, 6-min walking distance; BMI, body mass index; BMPR2,
bone morphogenetic protein receptor 2; miRNA, MicroRNA; PAP, pulmonary
artery pressure; PH, pulmonary hypertension.
(Lotvall et al., 2011)] (Hemnes et al., 2017). This is important
for personalized medicine for PH patients. The diverse molecular
nature of PH is underscored by our recent understanding of
mutations that can cause heritable PH. For example, recent work
has identified multiple genes in multiple different molecular
pathways that have gene-function altering mutations and confer
greatly increased risk for developing PH. Examples include
BMPR2 gene and other genes in the BMPR – transforming
growth factor signaling networks, potassium channel dysfunction
(KCNK3 gene), transcription factors, water channel (aquaporin
gene) (Eichstaedt et al., 2017; Kimura et al., 2017; Ma and Chung,
2017; Olschewski et al., 2017; Gräf et al., 2018). Further evidence
for the complex molecular cause of PH is that several risk factors
have to come together to trigger disease (Viales et al., 2015; Evans
et al., 2016).
MicroRNAs (miRNAs) function as epigenetic regulators of
gene expression. miRNAs are small non-coding RNAs that
negatively regulate gene expression by binding to the 3′UTR
(untranslated region) of target messenger RNAs (mRNAs),
thereby promoting mRNA degradation or suppressing the
translation of the mRNA, in both cases, limiting or suppressing
protein production from that specific gene. Currently, several
thousands of miRNAs have been identified, each miRNA binding
to several mRNAs, to control the function of several genes. In
contrast to mRNA, miRNAs are actively excreted by cells and
occur in the circulation (blood), miRNAs are very stable in bodily
fluids, and are conserved among species. The importance of
miRNA for PH has been established in recent studies (Bockmeyer
et al., 2012; Brock et al., 2012; White et al., 2012). miRNAs are
known for their critical function in gene-reprogramming that
occurs in response to hypoxia (Hale et al., 2012), and hypoxia
is an important cause for PH. Additionally, miR-204 has been
identified as a critical pathogenic mediator in experimental PH,
and it is down-regulated in human PH (Courboulin et al., 2011).
Several miRNAs, among them miR-21 or miR-20, have been
shown to target BMPR2 (Qin et al., 2009; Brock et al., 2012)
and to also have critical function for the hypoxia mediated
reprogramming of the pulmonary vasculature (Sarkar et al., 2010;
Brock et al., 2012; Yang et al., 2012).
The current studies were designed to test the idea that
circulating miRNA marker levels measured in the serum
or plasma would be associated with PH in an animal
model (Newman et al., 2015), and demonstrate significant
change following PH-alleviating supervised exercise training
(Grunig et al., 2012; Ehlken et al., 2016) or nightly oxygen
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(Schumacher et al., 2014; Ulrich et al., 2015) interventions in
human patients.
MATERIALS AND METHODS
Ethics Statement
All samples were from bio-repositories at the collaborating
institutions. Serum and plasma samples were obtained for
studies unrelated to the current experiments and then stored
in respective bio-repositories at the University of Colorado
(cattle plasma samples), or Universities of Zürich or Heidelberg
(human samples). The previous studies (Grunig et al., 2012a;
Schumacher et al., 2014; Newman et al., 2015; Ulrich et al., 2015;
Ehlken et al., 2016) were performed under the supervision of
the respective ethics committees at the collaborating institutions
with the consent that bio-repositories can be instituted. The
human participants gave written informed consent for blood
sample studies for the supervised exercise intervention (Ehlken
et al., 2016) and the nocturnal oxygen intervention (Ulrich et al.,
2015) studies, respectively. The blood samples were obtained
for other outcomes, unrelated to our study. For the current
studies, the samples were sent to us from our collaborators in
a de-identified manner, by persons not directly involved in the
current study, such that we would never be able to access the
link to the identifying data. For this reason, our research falls
under the category ‘no human or animal subjects involvement’
and therefore ethics approval was not required for this research
as per our Institution’s guidelines and national regulations.
Cattle Plasma Samples
Plasma samples were analyzed from groups of cattle that were
kept at high altitude (2300 m and higher) and that had received
approval by the Institutional Animal Use and Care Committee
at the University of Colorado (Newman et al., 2015). One group
of cattle remained healthy and tolerant of the altitude with mean
pulmonary artery pressures (mean PAP) of 50 mmHg and less
(Newman et al., 2015). The other group had exhibited signs of
intolerance to high altitude with mean PAP of 79 mmHg and
more. A few cattle had an intermediate response with mean PAP
of 50–79 mmHg.
Human Plasma and Serum Samples
De-identified, plasma and serum samples from bio-repositories
were received from two different centers at the Universities of
Heidelberg (Grunig et al., 2012a; Ehlken et al., 2016) and Zürich
(Schumacher et al., 2014; Ulrich et al., 2015), respectively. The
baseline characteristics of the sample donors are listed in Table 1,
and the diagnoses are summarized in Table 2. The study from
the Thoraxclinic, University of Heidelberg, had the goal to test
the treatment effects of a supervised exercise program that was
administered for the duration of 3 weeks in PH patients (Grunig
et al., 2012a; Ehlken et al., 2016). Paired serum samples had
been obtained before and after the supervised exercise program
for outcomes unrelated to our study. The samples were sent to
us from a repository. The study from the University of Zürich
had been designed to test the effects of nightly oxygen that
was administered in a randomized, double blinded manner to
PH patients (Schumacher et al., 2014; Ulrich et al., 2015). Each
patient was randomly assigned to placebo (air) or oxygen first,
and then was crossed-over to receive the other intervention.
Paired plasma samples were obtained from the placebo and the
oxygen parts of the study, respectively, for outcomes unrelated
to our study, each taken after 1-week duration of the placebo
or oxygen periods, respectively. Samples were sent to us from a
repository.
RNA Isolation
The same volume (200 µl) plasma or serum was used for
total RNA purification for all samples. Total RNA was purified
using miRNAeasy Mini Kit according to the protocol of the
manufacturer (Qiagen, Valencia, CA, United States) and eluted
into 35 µl of water. During RNA isolation process, after the lysis
and homogenization step of the manufacturer’s protocol, 1 µl
of UniSp6 RNA Spike-in template (representing 108 copies) was
added. The Spike RNA was used as an exogenous reference for the
miRNA measurements. The UniSp6 RNA Spike-in template was
provided with the miRCURY LNATM Universal cDNA synthesis
kit II (Exiqon, Woburn, MA, United States).
For all human plasma samples, we performed a heparinase
step following RNA purification. Thirty nanograms of RNA was
treated with the following mix: 0.3U of heparinase (H2519-
50UN, Sigma-Aldridge, St. Louis, MO, United States) and 22U
RNAse inhibitor (Invitrogen) re-suspended in 1xRT buffer from
miRCURY LNATM Universal cDNA synthesis kit II, for 1 h at
25◦C to remove heparin.
The cattle RNA was isolated in the same manner with
addition of dialysis step prior RNA isolation, because the cattle
samples were thought to contain citrate and heparin. Briefly,
TABLE 1 | Characteristics of sample populations.
U. Heidelberg U. Zürich
(Grunig et al., 2012a;
Ehlken et al., 2016)
exercise intervention
(Schumacher et al.,
2014; Ulrich et al., 2015)
oxygen intervention
Number of pairs 31 21
Age 50.68 ± 2.9351 65.14 ± 2.205
Gender Female 21 13
Male 10 8
NYHA class2 II 16 5
III 9 16
BMI (kg/m2) 28.28 ± 1.239 27.33 ± 0.892
6MWD (m) 459.5 ± 23.03 438.30 ± 19.79
PH with additional
diagnosis3
87% 100%
Mean PA pressure
(mmHg)
50.54 ± 3.383 40.50 ± 3.801
1Means ± SEM are indicated. 2 Information was not available for each of the
variables [e.g., NYHA (New York Heart Association) class of heart failure and mean
pulmonary artery (PA) pressure]. Of the patients with missing NYHA classification
(n = 6) the mean pulmonary artery pressures at rest were between 50 and
80 mmHg in three patients, and 40 mmHg in one patient. 3PH classifications and
Additional Diagnoses are listed in Table 2.
Frontiers in Physiology | www.frontiersin.org 3 July 2018 | Volume 9 | Article 955
fphys-09-00955 July 23, 2018 Time: 15:52 # 4
Grunig et al. Circulating MicroRNA Markers for Pulmonary Hypertension
TABLE 2 | Diagnoses for PH Patients.
U. Heidelberg U. Zürich
(exercise
intervention)
(oxygen
intervention)
Total number of PH patients 31 (100%) 21 (100%)
Primary diagnosis1
Idiopathic PAH 19 (61%) 12 (57%)
Heritable PAH 7 (22.6%)
Associated PAH
connective tissue disease 2 (6.5%) 1 (4.8%)
portal hypertension 2 (6.5%) 1 (4.8%)
congenital heart disease 1 (3.2%)
Chronic thromboembolic PH 7 (33%)
Additional diagnosis2
Number of patients who had
additional diagnoses
27 (87%) 21 (100%)
Transient embolic episodes of the
pulmonary artery
6 (19%)
Peripheral vascular disease
(hypertension, subdural hematoma,
arterial blockage, chronic venous
disease)
9 (29%) 8 (38%)
Chronic lung disease (COPD, airway
hyperreactivity, airway obstruction,
asthma)
8 (26%) 6 (28%)
Left heart disease and/or heart
rhythm abnormalities
7 (23%) 6 (28%)
Anemia, or iron therapy 8 (26%) 2 (9.5%)
Auto-immune disease (e.g., insulin
dependent diabetes, or autoimmune
thyroiditis)
3 (9.7%) 2 (9.5%)
Kidney disease 5 (16%) 5 (24%)
Tumor 2 (6.5%) 1 (4.8%)
1One primary diagnosis per patient. All patients received PH specific medication.
2One or more additional diagnoses per patient. The patients received diagnosis
specific medication as needed.
200 µl of sample in dialysis tube [Slide-A-Lyser Mini Dialysis
Unit, 2000 MWCO] (Thermo Fisher Scientific, Waltham, MA,
United States) was dialyzed against 200 ml of 1xTE (10 mM Tris-
HCl pH 8.0, 1 mM EDTA) at room temperature for 1 h. This was
followed by miRNAeasy Mini Kit extraction with addition of 108
copies UniSp6-Spike RNA and heparinase treatment.
Reverse transcriptase reaction was performed with miRCURY
LNATM Universal cDNA synthesis kit II accordingly to
manufacturer’s instructions. RNA concentrations were measured
with DS-11 spectrophotometer (DeNovix, Wilmington, DE,
United States).
miRNA Expression
Real time PCR was performed in triplicate with 0.1 ng of cDNA
per reaction using a 7900HT Fast Real-Time PCR instrument
(Applied Biosystems/Life Technologies, Grand Island, NY,
United States) in a 10 µl volume. The PCR reactions were
run with LNA-modified primers and SYBR Green master mix
(Exiqon, Denmark/now Qiagen) in 384-well plate under the
following conditions: 95◦C for 10 min, followed by 45 cycles of
95◦C for 10 s and 60◦C for 1 min, followed by a hold at 4◦C.
The following LNA-modified primers were used: hsa-miR-451a
(target 5′AAACCGUUACCAUUACUGAGUU); hsa-miR-22-3p
(target 5′AAGCUGCCAGUUGAAGAACUGU); hsa-miR-21-5p
(target 5′UAGCUUAUCAGACUGAUGUUGA); Spike6 (target
the synthetic spike RNA, UniSP6, supplied in the cDNA kit).
For the pilot study, we purchased LNA-modified primers
specific for 16 additional miRNAs (hsa-let-7g-5p, hsa-miR-17-
5p, hsa-miR-20a-5p, hsa-miR-20b-5p, hsa-miR-26a-5p, hsa-miR-
27a-3p, hsa-miR-27b-5p, hsa-miR-30e-3p, hsa-miR-30e-5p, hsa-
miR-93-5p, hsa-miR-103a-3p, hsa-miR-135a-5p, hsa-miR-142-
5p, hsa-miR-150-5p, hsa-miR-204-5p, Exiqon) and performed
real time PCR exactly as described above.
Raw data were then analyzed with SDS Relative Quantification
Software version 2.4.1 (Applied Biosystems) to determine
cycle threshold (Ct). The miRNA values that were calculated
relative to synthetic spike RNA used the following equation:
1.98 to the power of [Ct of spike6 RNA – Ct of miRNA
determinant], and then multiplied by 10,000 (human data) or
multiplied by 10 (cattle data). The composite miRNA values
were calculated as follows: 1.98 to the power of [Ct of miRNA
reference(s) – Ct of miRNA determinant(s)], and then multiplied
by 10,000. The miRNA values were calculated without knowledge
of the characteristics of the sample donors. The full data
sets that were calculated relative to synthetic spike RNA are
shown in Excel data files (Supplementary Files: cattle_data.xlsx;
human_large_sample_set.xlsx; human_large_mir_set.xlsx).
Statistical Analysis
Group comparisons were performed with the two-tailed,
independent Mann–Whitney U test, or the Wilcoxon matched
pairs signed rank test as indicated. Correlations were calculated
with the Spearman’s Rank Correlation test. Statistics were
calculated and graphs were generated using Prism 6 (GraphPad,
La Jolla, CA, United States). A p-value < 0.05 was considered to
be statistically significant.
Hierarchical clustering was performed to calculate principal
component analysis and to generate heatmaps with the freely
available online R-based tool ClustVis1 (Metsalu and Vilo,
2015). Unsupervised hierarchical clustering was performed using
Euclidean distance and complete linkage for columns (miRNA
value relative to spike RNA) and rows (sample ID). The heat map
graphs were re-oriented (columns and rows transposed) for best
display of the data.
RESULTS
Choice of miRNAs
Pilot studies were performed with RNA from whole
blood and serum (n = 12 and n = 6, respectively) from
paired samples from patients who had received exercise
training intervention. We utilized RNA sequencing of
whole blood RNA (data not shown) and literature mining
to choose 18 miRNAs for a pilot study in serum samples
1https://biit.cs.ut.ee/clustvis/
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(Supplementary Figure S1). Specific LNA-modified primers to
hsa-let-7g-5p, hsa-miR-17-5p, hsa-miR-20a-5p, hsa-miR-20b-5p,
hsa-miR-21-5p, hsa-miR-22-3p, hsa-miR-26a-5p, hsa-miR-
27a-3p, hsa-miR-27b-5p, hsa-miR-30e-3p, hsa-miR-30e-5p,
hsa-miR-93-5p, hsa-miR-103a-3p, hsa-miR-135a-5p, hsa-miR-
142-5p, hsa-miR-150-5p, hsa-miR-204-5p, and hsa-miR-451a
were detected by quantitative PCR and were calculated relative
to synthetic spike RNA (Supplementary Figure S1a). We
performed hierarchical cluster analysis to identify miRNAs that
would show changed levels when comparing samples taken
after and before training. We focused on the magnitude of the
change, irrespectively, of the direction of the change (increased
or decreased). Three miRNAs were most interesting: miR-22-3p,
miR-451a, and miR-21-5p (Supplementary Figure S1b). We
also searched for endogenous reference miRNAs that would
show little, if any variations among the samples, and did not
find clear candidates. However, a literature review indicated that
miR-451a had been considered as a reference miRNA (Song
et al., 2012), although in our samples this was not the case when
miR-451a was measured against the extrinsically added spike
RNA (Supplementary Figure S1).
Cattle Model of High Altitude Induced PH
Because the human PH condition is heterogeneous, we wanted to
test the miRNAs that we had identified in the pilot studies with
human samples (with focus on miR-22-3p and miR-451a) in an
animal model. High altitude induced PH was chosen because this
is a natural disease in cattle that has clearly identified etiology
(high altitude, with the decreased oxygen tension and hypoxia
challenge) with genetic predisposition in the EPAS-1 (Endothelial
PAS Domain-Containing Protein 1) gene, also known as hypoxia
inducible factor 2-alpha. Additional reasons to choose the cattle
model included the possibility to measure pulmonary arterial
pressures (PAP) by catheterization, even in the clinical setting,
and the cross-species conservation of the miRNAs between cattle
and human. Plasma samples from cattle that were tolerant to
high altitude (mean PAP less than 50 mmHg), cattle that had
developed PH (mean PAP more than 79 mmHg) and cattle with
intermediate mean PAP values were analyzed. The data showed
significantly decreased miR-22-3p determined relative to miR-
451a values in the plasma samples from the tolerant (control)
cattle, as compared to the intolerant and intermediate groups
(Figure 1). miR-22-3p and miR-451a are of molecular interest
in PH, particularly in PH associated with oxygen consumption,
because miR-22-3p has been shown to regulate muscle function,
including skeletal (Eisenberg et al., 2007; Schweisgut et al., 2017),
heart and smooth muscle (Huang et al., 2013; Huang and Wang,
2014; Zhao et al., 2015), control estrogen signaling by targeting
the estrogen receptor (Pandey and Picard, 2009), while miR-451a
controls erythrocyte function (Dore et al., 2008; Yu et al., 2010)
and skeletal muscle function (Davidsen et al., 2011).
Choice of Reference miRNAs for the
Human Test
Having confirmed the utility of miR-22-3p and miR-451a as
potential biomarkers for PH in the cattle model, we wanted
to further understand the relationships between the miRNA
measurements, including also miR-21-5p. Hierarchical cluster
analysis was performed on all data from both intervention
studies (exercise or oxygen, respectively, with 52 donors and
104 samples in total). The results are presented in a heatmap
display (Supplementary Figure S2). The cluster analysis showed
that miR-21-5p and miR-22-3p clustered together, separately
from miR-451a, Additionally, the clustered miRNA’s separated
the before and after intervention measurements in 46 donors, and
only 6 donor data clustered together (Supplementary Figure S2).
For miR-22-3p relative to miR-451a and additionally for
each of the studied miRNA’s we calculated the miRNA level
values relative to spike RNA and determined the fold change
after training or oxygen, respectively. We then determined
correlations of the fold-change values (Table 3). The calculations
showed that the fold change determined in miR-22-3p (relative to
spike) was significantly correlated with the fold change in miR-
21-5p (relative to spike) in both the training and the oxygen
intervention studies, respectively (Table 3). This prompted us
to also compare the fold-change in composite miRNA values,
combining miR-22-3p and miR-21-5p, as a way to diminish the
significance of technical variations (minute pipetting errors for
example) as causes for variations in the qPCR quantification
FIGURE 1 | Circulating plasma miRNA values in cattle at high altitude.
Box-plots with whiskers and individual points show miR-22-3p relative to
miR-451a (10,000×) values in plasma samples from control cattle that were
tolerant to high altitude [mean pulmonary artery pressure, mean PAP, <50 mm
Hg (Newman et al., 2015)], or that developed PH (mean PAP ≥79 mmHg), or
that had intermediate mean PAP. Groups were compared with the unpaired,
2-tailed Mann–Whitney test; p < 0.05 was considered significant.
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values. As for the reference miRNA composite choice, we used
miR-451a plus spike RNA, because spike RNA is the invariant
component of our test, as the same number of copies (108) of
spike RNA were added to each 200µl of sample used for the RNA
isolation. The composite miRNA marker was then calculated
as miR-22-3p + miR-21-5p relative to miR-451a + spike RNA.
The composite marker (miR-22-3p+miR-21-5p relative to miR-
451a + spike RNA) was significantly correlated with the values
for miR-22-3p relative to miR-451a in both the exercise training
and oxygen intervention studies, respectively (Table 3).
TABLE 3 | Correlations between different types of miRNA measurement readouts.
(A) miRNA marker change following exercise training intervention (n = 31 pairs).
X – Variable miR-22/miR451 miR-22/miR451 miR-22/miR451 miR-22/spike miR-451/spike miR-22/miR451
Y – Variable miR-22/spike miR-451/spike miR-21/spike miR-21/spike miR-21/spike miR-22 + miR-21/miR-
451 + spike
Spearman’s R 0.3156 −0.348 0.09699 0.704 0.629 0.5986
P-Value 0.0838 0.055 0.6037 <0.0001 0.0002 0.0004
(B) miRNA marker change following nightly oxygen intervention (n = 21 pairs).
X – Variable miR-22/miR451 miR-22/miR451 miR-22/miR451 miR-22/spike miR-451/spike miR-22/miR451
Y – Variable miR-22/spike miR-451/spike miR-21/spike miR-21/spike miR-21/spike miR-22 + miR-21/miR-
451 + spike
Spearman’s R 0.7636 −0.2558 0.3143 0.5221 0.2494 0.8688
P-Value <0.0001 0.2630 0.1653 0.0152 0.2757 <0.0001
Correlations and significance were calculated with Spearman’s rank correlation test on the fold-change after training relative to baseline, or oxygen relative to placebo,
respectively. A p < 0.05 was considered significant (bold).
FIGURE 2 | Circulating serum miRNA values in the supervised exercise training intervention study. Symbols and lines graphs show miR-22-3p relative to miR-451a
(10,000×) values (A,B), or miR-22-3p + miR-21-5p relative to spike-RNA + miR-451a (10,000×) values (C,D) in serum samples obtained from patients (Ehlken
et al., 2016; Grunig et al., 2012a) before and after exercise training intervention. All of the data are plotted in (A,C); in (B,D) the data are separated by the directional
change in the samples after exercise training intervention. Groups before and after intervention were compared with the Wilcoxon matched pairs signed rank test;
p < 0.05 was considered significant.
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miRNA Value Changes After Supervised
Exercise Training or Oxygen
Interventions
We used miR-22-3p relative to miR-451a and miR-22-3p+miR-
21-5p relative to miR-451a + spike RNA values to compare
changes following supervised exercise training (Figures 2, 3)
or nightly oxygen (Figures 4, 5), respectively. In the exercise
intervention, the serum levels of miR-22-3p relative to miR-
451a were significantly decreased (p = 0.012) following training,
however, the direction of change was clearly increased in
some of the samples (Figure 2A). The divergence of the
direction of the change in miRNA values could be clearly
shown by dividing the samples based on the direction of the
fold change (Figure 2B). The divergence of the direction of
change in miRNA values was even more pronounced when
miR-22-3p + miR-21-5p relative to miR-451a + spike RNA
was calculated (Figures 2C,D). Comparing miRNA directional
changes to baseline disease characteristics we found a significant
difference in the 6-min-walking distance (Figure 3). Samples that
showed a decreased directional change in the miRNA marker
[miR-22-3p + miR-21-5p relative to miR-451a + spike RNA]
(Figure 2D) were obtained from patients who had a significantly
longer 6-min-walking distance at baseline (Figure 3). For this
analysis, we omitted samples from 3 patients who had a BMI
greater that 40 kg/m2 and who achieved 6-min-walking-distances
between 150 and 190 m.
The data from the nightly oxygen intervention study showed
that we measured higher miRNA marker values as compared to
the values measured in the exercise intervention study (Figure 4
compared to Figure 2). This is likely due to the different
materials being studied: serum in the exercise intervention study
(Figure 2), plasma in the oxygen intervention study (Figure 4).
FIGURE 3 | Baseline 6-min walking distance in the exercise training intervention study - comparison with directional change of the miRNA marker. Box-plots with
whiskers and individual points show 6-min-walking-distance (6MWD, m) measured at baseline examination from patients in the exercise training intervention study.
The data were grouped by the directional change of the miR-22-3p + miR-21-5p relative to spike-RNA + miR-451a (10,000×) values after versus before exercise
training intervention: down or up, as shown in Figure 2D. Groups were compared with the unpaired, 2-tailed Mann–Whitney test; p < 0.05 was considered
significant, ns is not significant. The table graph lists the characteristics of the sample donors for each group. For this analysis, samples from three patients who had
a body mass index (BMI) greater that 40 kg/m2 and who achieved 6-min-walking-distances between 150 and 190 m were omitted; two of these three patients were
NYHA class III, one was NYHA class not determined.
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FIGURE 4 | Circulating serum miRNA values in the oxygen intervention study. Symbols and lines graphs show miR-22-3p relative to miR-451a (10,000×) values
(A,B), or miR-22-3p + miR-21-5p relative to spike-RNA + miR-451a (10,000×) values (C,D) in plasma samples obtained from patients (Schumacher et al., 2014;
Ulrich et al., 2015) given placebo (air) or oxygen in a cross-over design. All of the data are plotted in (A,C); in (B,D) the data are separated by the directional change
in the samples after oxygen intervention. Groups before and after intervention were compared with the Wilcoxon matched pairs signed rank test; p < 0.05 was
considered significant.
This idea is supported by the data from cattle plasma samples
that show miRNA marker values in a similar range as the
human plasma samples (Figure 1 compared to Figure 4). As
observed in the exercise intervention study (Figure 2), the
oxygen intervention study showed that significant changes in
the direction of the miRNA values followed individual variation,
with approximately half demonstrating decreased, and the other
half increased miRNA marker values (Figure 4). This was found
both with miRNA marker values being calculate by miR-22-3p
relative to miR-451a, or miR-22-3p + miR-21-5p relative to
miR-451a + spike RNA (Figures 4B,D). To understand if the
fold change difference could represent different PH endotypes,
we compared the groups of patients whose miRNA value was
either significantly decreased or increased following oxygen
intervention. We found a significant difference between these
groups in the 6MWD recorded at baseline (Figure 5). As we
had already seen in the data from the exercise intervention study
(Figure 3), the group that had an upward change in the miRNA
marker following oxygen intervention had a significantly lower
6-min-walking-distance at baseline (Figure 5). Further, in both
intervention studies, there was a higher percentage of males
in the group with an upward direction of the miRNA marker
change, but the difference to the group that had a down-ward
change was not significant (Figures 3, 5). To further confirm
the possibility that the 6-min-walking-distance at baseline could
predict, or be correlated, with the directional, fold-change of the
miRNA marker following intervention, we plotted fold-change
of serum or plasma miR-22-3p + miR-21-5p relative to miR-
451a+ spike RNA (Figure 6). The data from the exercise training
and the nightly oxygen intervention studies were combined to
increase the number of observations for analysis and to query
for generalizable impact (Figure 6). For this analysis, we omitted
samples from three patients who had a BMI greater that 40 kg/m2
and who achieved 6-min-walking-distances between 150 and
190 m. The analysis showed a significant correlation calculated
with Spearman’s rank correlation test between 6MWD at baseline
and the fold change of the miRNA marker (miR-22-3p+miR-21-
5p relative to miR-451a+ spike RNA, Figure 6).
DISCUSSION
Our studies identified circulating miRNA markers composed of
miR-21, miR-22, and miR-451 that showed significant change
in a natural animal model (Newman et al., 2015), and in two
intervention studies [supervised exercise training (Grunig et al.,
2012a; Ehlken et al., 2016) and nightly oxygen (Schumacher et al.,
2014; Ulrich et al., 2015)] in human PH patients. In the human
studies, the change in miRNA value following intervention was
significantly correlated with the 6MWD at baseline. While the
present study did not evaluate the genes (mRNA) controlled
by the miRNAs, a literature search shows that, for example,
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FIGURE 5 | Baseline 6-min walking distance in the oxygen intervention study – comparison with directional change of the miRNA marker. Box-plots with whiskers
and individual points show 6-min-walking-distance (6MWD, m) measured at baseline examination from patients in the oxygen intervention study. The data were
grouped by the directional change of the miR-22-3p + miR-21-5p relative to spike-RNA + miR-451a (10,000×) values after oxygen versus placebo: down or up, as
shown in Figure 4D. Groups were compared with the unpaired, 2-tailed Mann–Whitney test; p < 0.05 was considered significant, ns is not significant. The table
graph lists the characteristics of the sample donors for each group.
miR-21 directly targets BMPR2 (Qin et al., 2009). Both miR-
21 and miR-22 control fibrosis in the lungs (Liu et al., 2010),
or kidney, respectively (Long et al., 2013). Further, miR-21
and miR-22 are dysregulated in some primary muscle diseases
(Eisenberg et al., 2007) and miR-451 is differentially regulated in
low and high responders of a specific muscle training program
of healthy volunteers (Davidsen et al., 2011). miR-22 is also a
critical regulator of cardiac muscle health, and smooth muscle
differentiation (Huang et al., 2013; Huang and Wang, 2014; Zhao
et al., 2015). miR-451a is a critical regulator of erythropoiesis and
erythrocyte function (Dore et al., 2008; Yu et al., 2010).
Our data add to the knowledge of miRNA function in PH
(Bockmeyer et al., 2012; White et al., 2012; Deng et al., 2015;
Caruso et al., 2017) that has thus far mainly focused on miRNA
control of endothelial cells (Huertas et al., 2018), vascular smooth
muscle cells, the right heart, the important PH risk factor gene,
BMPR2, and the PH inducing hypoxia miRNAs (hypoxamirs),
with particular significance of miR-204 (Courboulin et al., 2011),
miR-20 (Brock et al., 2012), and miR-21 (Qin et al., 2009; Sarkar
et al., 2010; Yang et al., 2012). miRNAs have been further shown
to have critical significance for the dysfunction of endothelial cell
metabolism and function (miR-124) in PH and mitochondrial
dysfunction of fission and calcium transport causing hyper-
proliferation of smooth muscle cells (miR-34a-3p, miR-138, miR-
25) in PH (Caruso et al., 2017; Hong et al., 2017; Chen et al.,
2018).
Our studies highlight the significance of skeletal muscle
function in PH as miR-21, miR-22, and miR-451a share skeletal
muscle as one of their cellular targets (Eisenberg et al., 2007;
Davidsen et al., 2011; Schweisgut et al., 2017). Furthermore, miR-
451 is known for its control of erythrocyte function (Dore et al.,
2008; Yu et al., 2010). This may be the reason why the composite
miRNA marker value that contained miR-22, miR-21, miR-451a,
and spike-RNA was correlated with the 6-min-walking distance
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FIGURE 6 | Correlation between change in miRNA marker and 6-min-walking-distance, supervised exercise training and nightly oxygen intervention data combined.
The fold-change in miR-22-3p + miR-21-5p relative to spike-RNA + miR-451a (10,000×) values (after/before exercise, or oxygen/placebo, respectively) were plotted
against 6-min walking distance (m) measured at baseline examination from the patients. The data from the exercise training intervention study were plotted with ×
symbols, and the data from the nightly oxygen intervention study were plotted as clear/black-filled diamond symbols. The black-filled diamond represents one outlier
data point, and correlations were calculated with and without the outlier point as indicated. The correlation was calculated with Spearman’s rank correlation test;
p < 0.05 was considered significant. For this analysis, samples from three patients who had a body mass index (BMI) greater that 40 kg/m2 and who achieved
6-min-walking-distances between 150 and 190 m were omitted.
measured at baseline by the patients who participated in the
exercise training intervention or oxygen intervention studies,
respectively. Skeletal muscle function and optimal erythrocyte
transport of oxygen are critical for achieving optimal walking
distances, and muscle wasting has been described in PH patients
(Marra et al., 2015). Optimized erythrocyte function is an
important adaptation to high altitude hypoxia (Song et al., 2017).
It is intriguing that miR-451a has been described as one of
the miRNAs that demonstrate differential response directions in
healthy young men who underwent resistance exercise training
and had varying degrees of muscle mass gain (Davidsen et al.,
2011). Therefore, future studies have to be designed to distinguish
between the possibilities that the divergent directional changes in
miRNA marker values that we observed, are already an intrinsic
personal trait due to skeletal muscle responsiveness prior to the
development of PH, or are developed as consequence of the PH
disease.
Our studies provide an example for the importance of using
animal models for biomarker discovery in PH because of the
variations intrinsic to human disease. In our case, there was no
optimal experimental mouse or rat model of exercise or oxygen
intervention in PH available. The cattle model has the advantages
of being a natural disease, and, importantly, control as well as
PH cattle are perfectly matched (Newman et al., 2015). Control
animals share the same environment as the animals that develop
to PH including high altitude, food, pasture, animal housing
(Newman et al., 2015). In contrast, in experimental models
of hypoxia induced PH, the experimental group is exposed to
hypoxia, the control group is not. In our case where the goal was
to identify miRNA markers that track PH, it was essential that
the control animal group was also exposed to hypoxia, as hypoxia
itself induces changes in the expression of a large set of miRNA
markers, called hypoxamirs (Hale et al., 2012). Furthermore, our
data in cattle may be hypothesis generating to further develop
the understanding of the regulation of PAP at high altitude in
humans by miRNAs (Blissenbach et al., 2018).
Our study in samples from human patients was designed with
the heterogeneity of PH in focus, although all patients responded
favorably to the supervised exercise training intervention (Grunig
et al., 2012a; Ehlken et al., 2016), or nightly oxygen (Schumacher
et al., 2014; Ulrich et al., 2015) intervention, respectively. The
heterogeneity of PH is highlighted by the heterogeneity of gene
mutations in heritable PH (Eichstaedt et al., 2017; Ma and Chung,
2017; Gräf et al., 2018). The heterogeneity of the underlying
molecular mechanisms that cause disease has prompted the
development of tools for personalized medicine (Hemnes et al.,
2017). Big data, OMICS studies are currently conducted to fine-
map clinical, physiological, imaging and molecular parameters
that are then used to better define clinical subtypes and to identify
disease endotypes (Hemnes et al., 2017). One example in PH
is the pulmonary vascular disease OMICS (PVDOMICS) study
(Hemnes et al., 2017). Our study, in contrast, did not have the
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power based on thousands of individual data points to draw
this fine-map of PH. Instead we used three different sample
cohorts to identify miRNA markers that would demonstrate
significant changes in the biomarker: a high altitude animal
model of PH (Newman et al., 2015), and PH interventions
in humans consisting either of supervised exercise training
(Grunig et al., 2012a; Ehlken et al., 2016) or nightly oxygen
(Schumacher et al., 2014; Ulrich et al., 2015). The significant
difference in the homogenous animal model, in contrast to
the individual differences in the direction of the change of
the miRNA marker together with differences among groups
with respect to baseline 6-min-walking-distance in human PH,
implies that the biomarker may have distinguished PH endotypes.
However, further studies using large patient cohorts are needed to
confirm this idea.
CONCLUSION
Our analysis identified circulating miRNAs that control muscle
and erythrocyte function (miR-22-3p, miR-21-5p, miR-451a) that
may have utility as biomarkers of PH progression and responses
to intervention. The strength of our data is in the consistency
across different patient groups given supervised exercise training
or oxygen intervention, respectively, consistency across sample
processes (serum versus plasma), and confirmation in a natural
animal model. Further research in larger patient groups and in
additional data sets is needed to validate our data and to test
the idea that different PH endotypes are, in part, the cause for
the individual variation in the direction of the miRNA marker
changes in response to the training or oxygen interventions.
Future studies will also need to address the relationship between
the miRNA markers and commonly used markers in PH (e.g.,
B-type natriuretic peptide). Furthermore, future studies will
need to be designed to identify the molecular mechanisms by
which exercise training or oxygen interventions provide feed-
back signals via the changed levels of circulating miRNAs to
the pulmonary vasculature, and the clinical PH phenotype,
because miR-21 and miR-22 also have functions in the pulmonary
vasculature (Sarkar et al., 2010; Yang et al., 2012; Zhao et al., 2015)
and in the heart (Huang et al., 2013; Huang and Wang, 2014).
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FIGURE S1 | Hierarchical clustering of serum miRNA levels determined relative to
synthetic spike RNA from samples obtained before (B) or after (A) exercise
intervention. (a) Full pilot study miRNA panel. Note that miR-22-3p and miR-21-5p
are in clusters distinct from miR-451a. Also note that samples from a single donor
are listed together (box) but not clustered together. (b) Selected miRNAs. Note
that miR-22-3p and miR-21-5p are clustered together apart from miR-451a. Note
that none of the paired samples are listed together.
FIGURE S2 | Hierarchical clustering of serum or plasma miRNA levels determined
relative to synthetic spike RNA from n = 52 paired samples, total n = 104. The
samples were obtained before (B) or after (A) exercise intervention at the University
of Heidelberg (HD), or following placebo (P) or oxygen (O) intervention at the
University of Zurich (ZH), respectively. Samples from 46 donors clustered apart;
the samples from 6 donors were either listed or clustered together and are
indicated (boxes).
REFERENCES
Becker-Grunig, T., Klose, H., Ehlken, N., Lichtblau, M., Nagel, C., Fischer, C.,
et al. (2013). Efficacy of exercise training in pulmonary arterial hypertension
associated with congenital heart disease. Int. J. Cardiol. 168, 375–381.
doi: 10.1016/j.ijcard.2012.09.036
Blissenbach, B., Nakas, C. T., Kronke, M., Geiser, T., Merz, T. M., and Pichler
Hefti, J. (2018). Hypoxia-induced changes in plasma micro-RNAs correlate
with pulmonary artery pressure at high altitude. Am. J. Physiol. Lung Cell. Mol.
Physiol. 314, L157–L164. doi: 10.1152/ajplung.00146.2017
Bockmeyer, C. L., Maegel, L., Janciauskiene, S., Rische, J., Lehmann, U., Maus,
U. A., et al. (2012). Plexiform vasculopathy of severe pulmonary arterial
hypertension and microRNA expression. J. Heart Lung Transplant. 31, 764–772.
doi: 10.1016/j.healun.2012.03.010
Brock, M., Samillan, V. J., Trenkmann, M., Schwarzwald, C., Ulrich, S., Gay,
R. E., et al. (2012). AntagomiR directed against miR-20a restores functional
BMPR2 signalling and prevents vascular remodelling in hypoxia-induced
pulmonary hypertension. Eur. Heart J. 35, 3203–3211. doi: 10.1093/eurheartj/
ehs060
Caruso, P., Dunmore, B. J., Schlosser, K., Schoors, S., Dos Santos, C., Perez-
Iratxeta, C., et al. (2017). Identification of MicroRNA-124 as a major regulator
of enhanced endothelial cell glycolysis in pulmonary arterial hypertension
via PTBP1 (polypyrimidine tract binding protein) and pyruvate kinase m2.
Circulation 136, 2451–2467. doi: 10.1161/CIRCULATIONAHA.117.028034
Chen, K. H., Dasgupta, A., Lin, J., Potus, F., Bonnet, S., Iremonger, J., et al.
(2018). Epigenetic dysregulation of the Drp1 binding partners MiD49 and
MiD51 increases mitotic mitochondrial fission and promotes pulmonary
arterial hypertension: mechanistic and therapeutic implications. Circulation
doi: 10.1161/CIRCULATIONAHA.117.031258 [Epub ahead of print].
Courboulin, A., Paulin, R., Giguere, N. J., Saksouk, N., Perreault, T., Meloche, J.,
et al. (2011). Role for miR-204 in human pulmonary arterial hypertension.
J. Exp. Med. 208, 535–548. doi: 10.1084/jem.20101812
Davidsen, P. K., Gallagher, I. J., Hartman, J. W., Tarnopolsky, M. A., Dela, F., Helge,
J. W., et al. (2011). High responders to resistance exercise training demonstrate
differential regulation of skeletal muscle microRNA expression. J. Appl. Physiol.
110, 309–317. doi: 10.1152/japplphysiol.00901.2010
Deng, L., Blanco, F. J., Stevens, H., Lu, R., Caudrillier, A., McBride, M., et al.
(2015). MicroRNA-143 activation regulates smooth muscle and endothelial
cell crosstalk in pulmonary arterial hypertension. Circ. Res. 117, 870–883.
doi: 10.1161/CIRCRESAHA.115.306806
Dore, L. C., Amigo, J. D., Dos Santos, C. O., Zhang, Z., Gai, X., Tobias, J. W.,
et al. (2008). A GATA-1-regulated microRNA locus essential for erythropoiesis.
Proc. Natl. Acad. Sci. U.S.A. 105, 3333–3338. doi: 10.1073/pnas.071231
2105
Ehlken, N., Lichtblau, M., Klose, H., Weidenhammer, J., Fischer, C., Nechwatal, R.,
et al. (2016). Exercise training improves peak oxygen consumption and
haemodynamics in patients with severe pulmonary arterial hypertension and
inoperable chronic thrombo-embolic pulmonary hypertension: a prospective,
Frontiers in Physiology | www.frontiersin.org 11 July 2018 | Volume 9 | Article 955
fphys-09-00955 July 23, 2018 Time: 15:52 # 12
Grunig et al. Circulating MicroRNA Markers for Pulmonary Hypertension
randomized, controlled trial. Eur. Heart J. 37, 35–44. doi: 10.1093/eurheartj/
ehv337
Eichstaedt, C. A., Song, J., Viales, R. R., Pan, Z., Benjamin, N., Fischer, C.,
et al. (2017). First identification of Kruppel-like factor 2 mutation in heritable
pulmonary arterial hypertension. Clin. Sci. 131, 689–698. doi: 10.1042/
CS20160930
Eisenberg, I., Eran, A., Nishino, I., Moggio, M., Lamperti, C., Amato, A. A.,
et al. (2007). Distinctive patterns of microRNA expression in primary muscular
disorders. Proc. Natl. Acad. Sci. U.S.A. 104, 17016–17021. doi: 10.1073/pnas.
0708115104
Evans, J. D., Girerd, B., Montani, D., Wang, X. J., Galie, N., Austin, E. D., et al.
(2016). BMPR2 mutations and survival in pulmonary arterial hypertension:
an individual participant data meta-analysis. Lancet Respir. Med. 4, 129–137.
doi: 10.1016/S2213-2600(15)00544-5
Gonzalez-Saiz, L., Fiuza-Luces, C., Sanchis-Gomar, F., Santos-Lozano, A.,
Quezada-Loaiza, C. A., Flox-Camacho, A., et al. (2017). Benefits of skeletal-
muscle exercise training in pulmonary arterial hypertension: the WHOLEi+12
trial. Int. J. Cardiol. 231, 277–283. doi: 10.1016/j.ijcard.2016.12.026
Gräf, S., Haimel, M., Bleda, M., Hadinnapola, C., Southgate, L., Li, W., et al. (2018).
Identification of rare sequence variation underlying heritable pulmonary
arterial hypertension. Nat. Commun. 9:1416. doi: 10.1038/s41467-018-03672-4
Grunig, E., Ehlken, N., Ghofrani, A., Staehler, G., Meyer, F. J., Juenger, J., et al.
(2011). Effect of exercise and respiratory training on clinical progression and
survival in patients with severe chronic pulmonary hypertension. Respiration
81, 394–401. doi: 10.1159/000322475
Grunig, E., Lichtblau, M., Ehlken, N., Ghofrani, H. A., Reichenberger, F.,
Staehler, G., et al. (2012a). Safety and efficacy of exercise training in various
forms of pulmonary hypertension. Eur. Respir J. 40, 84–92. doi: 10.1183/
09031936.00123711
Grunig, E., Maier, F., Ehlken, N., Fischer, C., Lichtblau, M., Blank, N., et al. (2012b).
Exercise training in pulmonary arterial hypertension associated with connective
tissue diseases. Arthritis Res. Ther. 14:R148. doi: 10.1186/ar3883
Hale, A. E., White, K., and Chan, S. Y. (2012). Hypoxamirs in pulmonary
hypertension: breathing new life into pulmonary vascular research. Cardiovasc.
Diagnosis Ther. 2, 200–212.
Hemnes, A. R., Beck, G. J., Newman, J. H., Abidov, A., Aldred, M. A., Barnard, J.,
et al. (2017). PVDOMICS: a multi-center study to improve understanding of
pulmonary vascular disease through phenomics. Circ. Res. 121, 1136–1139.
doi: 10.1161/CIRCRESAHA.117.311737
Hoffmann, J., Wilhelm, J., Olschewski, A., and Kwapiszewska, G. (2016).
Microarray analysis in pulmonary hypertension. Eur. Respir. J. 48, 229–241.
doi: 10.1183/13993003.02030-2015
Hong, Z., Chen, K. H., DasGupta, A., Potus, F., Dunham-Snary, K., Bonnet, S.,
et al. (2017). MicroRNA-138 and MicroRNA-25 down-regulate mitochondrial
calcium uniporter, causing the pulmonary arterial hypertension cancer
phenotype. Am. J. Respir. Crit. Care Med. 195, 515–529. doi: 10.1164/rccm.
201604-0814OC
Huang, Z. P., Chen, J., Seok, H. Y., Zhang, Z., Kataoka, M., Hu, X., et al. (2013).
MicroRNA-22 regulates cardiac hypertrophy and remodeling in response to
stress. Circ. Res. 112, 1234–1243. doi: 10.1161/CIRCRESAHA.112.300682
Huang, Z. P., and Wang, D. Z. (2014). miR-22 in cardiac remodeling and disease.
Trends Cardiovasc. Med. 24, 267–272. doi: 10.1016/j.tcm.2014.07.005
Huertas, A., Guignabert, C., Barberà, J. A., Bärtsch, P., Bhattacharya, J., and
Bhattacharya, S. (2018). Pulmonary vascular endothelium: orchestra conductor
in respiratory diseases highlights from basic research to therapy. Eur. Respir. J.
51, 1700745. doi: 10.1183/13993003.00745-2017
Keusch, S., Turk, A., Saxer, S., Ehlken, N., Grunig, E., Ulrich, S., et al. (2017).
Rehabilitation in patients with pulmonary arterial hypertension. Swiss. Med.
Wkly. 147:w14462. doi: 10.4414/smw.2017.14462
Kimura, M., Tamura, Y., Guignabert, C., Takei, M., Kosaki, K., Tanabe, N., et al.
(2017). A genome-wide association analysis identifies PDE1A| DNAJC10 locus
on chromosome 2 associated with idiopathic pulmonary arterial hypertension
in a Japanese population. Oncotarget 8, 74917–74926. doi: 10.18632/oncotarget.
20459
Leggio, M., Fusco, A., Armeni, M., D’Emidio, S., Severi, P., Calvaruso, S., et al.
(2018). Pulmonary hypertension and exercise training: a synopsis on the more
recent evidences. Ann. Med. 50, 226–233. doi: 10.1080/07853890.2018.1432887
Liu, G., Friggeri, A., Yang, Y., Milosevic, J., Ding, Q., Thannickal, V. J.,
et al. (2010). miR-21 mediates fibrogenic activation of pulmonary fibroblasts
and lung fibrosis. J. Exp. Med. 207, 1589–1597. doi: 10.1084/jem.2010
0035
Long, J., Badal, S. S., Wang, Y., Chang, B. H., Rodriguez, A., and Danesh, F. R.
(2013). MicroRNA-22 is a master regulator of bone morphogenetic protein-7/6
homeostasis in the kidney. J. Biol. Chem. 288, 36202–36214. doi: 10.1074/jbc.
M113.498634
Lotvall, J., Akdis, C. A., Bacharier, L. B., Bjermer, L., Casale, T. B., Custovic, A.,
et al. (2011). Asthma endotypes: a new approach to classification of disease
entities within the asthma syndrome. J. Allergy Clin. Immunol. 127, 355–360.
doi: 10.1016/j.jaci.2010.11.037
Ma, L., and Chung, W. K. (2017). The role of genetics in pulmonary arterial
hypertension. J. Pathol. 241, 273–280. doi: 10.1002/path.4833
Marra, A. M., Arcopinto, M., Bossone, E., Ehlken, N., Cittadini, A., and Grunig, E.
(2015). Pulmonary arterial hypertension-related myopathy: an overview of
current data and future perspectives. Nutr. Metab. Cardiovasc. Dis. 25, 131–139.
doi: 10.1016/j.numecd.2014.10.005
Mereles, D., Ehlken, N., Kreuscher, S., Ghofrani, S., Hoeper, M. M., Halank, M.,
et al. (2006). Exercise and respiratory training improve exercise capacity
and quality of life in patients with severe chronic pulmonary hypertension.
Circulation 114, 1482–1489. doi: 10.1161/CIRCULATIONAHA.106.618397
Metsalu, T., and Vilo, J. (2015). ClustVis: a web tool for visualizing clustering
of multivariate data using principal component analysis and heatmap. Nucleic
Acids Res. 43, W566–W570. doi: 10.1093/nar/gkv468
Moreira-Goncalves, D., Ferreira-Nogueira, R., Santos, M., Silva, A. F., Ferreira, R.,
Leite-Moreira, A., et al. (2017). Exercise training in pulmonary hypertension
and right heart failure: insights from pre-clinical studies. Adv. Exp. Med. Biol.
999, 307–324. doi: 10.1007/978-981-10-4307-9_17
Nagel, C., Prange, F., Guth, S., Herb, J., Ehlken, N., Fischer, C., et al. (2012).
Exercise training improves exercise capacity and quality of life in patients with
inoperable or residual chronic thromboembolic pulmonary hypertension. PLoS
One 7:e41603. doi: 10.1371/journal.pone.0041603
Newman, J. H., Holt, T. N., Cogan, J. D., Womack, B., Phillips, J. A. III, Li, C.,
et al. (2015). Increased prevalence of EPAS1 variant in cattle with high-altitude
pulmonary hypertension. Nat. Commun. 6:6863. doi: 10.1038/ncomms7863
Olschewski, A., Veale, E. L., Nagy, B. M., Nagaraj, C., Kwapiszewska, G.,
Antigny, F., et al. (2017). TASK-1 (KCNK3) channels in the lung: from cell
biology to clinical implications. Eur. Respir. J. 50, 1700754. doi: 10.1183/
13993003.00754-2017
Pandey, A., Garg, S., Khunger, M., Garg, S., Kumbhani, D. J., Chin, K. M.,
et al. (2015). Efficacy and Safety of Exercise Training in Chronic Pulmonary
Hypertension: Systematic Review and Meta-Analysis. Circ Heart Fail 8,
1032–1043. doi: 10.1161/CIRCHEARTFAILURE.115.002130
Pandey, D. P., and Picard, D. (2009). miR-22 inhibits estrogen signaling by directly
targeting the estrogen receptor alpha mRNA. Mol. Cell. Biol. 29, 3783–3790.
doi: 10.1128/MCB.01875-08
Qin, W., Zhao, B., Shi, Y., Yao, C., Jin, L., and Jin, Y. (2009). BMPRII is a direct
target of miR-21. Acta Biochim. Biophys. Sin. 41, 618–623. doi: 10.1093/abbs/
gmp049
Richter, M. J., Grimminger, J., Kruger, B., Ghofrani, H. A., Mooren, F. C.,
Gall, H., et al. (2017). Effects of exercise training on pulmonary hemodynamics,
functional capacity and inflammation in pulmonary hypertension. Pulm. Circ.
7, 20–37. doi: 10.1086/690553
Sarkar, J., Gou, D., Turaka, P., Viktorova, E., Ramchandran, R., and Raj, J. U.
(2010). MicroRNA-21 plays a role in hypoxia-mediated pulmonary artery
smooth muscle cell proliferation and migration. Am. J. Physiol. Lung Cell. Mol.
Physiol. 299, L861–L871. doi: 10.1152/ajplung.00201.2010
Schumacher, D. S., Muller-Mottet, S., Hasler, E. D., Hildenbrand, F. F.,
Keusch, S., Speich, R., et al. (2014). Effect of oxygen and acetazolamide on
nocturnal cardiac conduction, repolarization, and arrhythmias in precapillary
pulmonary hypertension and sleep-disturbed breathing. Chest 146, 1226–1236.
doi: 10.1378/chest.14-0495
Schweisgut, J., Schutt, C., Wust, S., Wietelmann, A., Ghesquiere, B., Carmeliet, P.,
et al. (2017). Sex-specific, reciprocal regulation of ERalpha and miR-22 controls
muscle lipid metabolism in male mice. EMBO J. 36, 1199–1214. doi: 10.15252/
embj.201695988
Frontiers in Physiology | www.frontiersin.org 12 July 2018 | Volume 9 | Article 955
fphys-09-00955 July 23, 2018 Time: 15:52 # 13
Grunig et al. Circulating MicroRNA Markers for Pulmonary Hypertension
Simonneau, G., Gatzoulis, M. A., Adatia, I., Celermajer, D., Denton, C.,
Ghofrani, A., et al. (2013). Updated clinical classification of pulmonary
hypertension. J. Am. Coll. Cardiol. 62, D34–D41. doi: 10.1016/j.jacc.2013.10.029
Song, A., Zhang, Y., Han, L., Yegutkin, G. G., Liu, H., Sun, K., et al. (2017).
Erythrocytes retain hypoxic adenosine response for faster acclimatization upon
re-ascent. Nat. Commun. 8:14108. doi: 10.1038/ncomms14108
Song, J., Bai, Z., Han, W., Zhang, J., Meng, H., Bi, J., et al. (2012). Identification of
suitable reference genes for qPCR analysis of serum microRNA in gastric cancer
patients. Dig. Dis. Sci. 57, 897–904. doi: 10.1007/s10620-011-1981-7
Ulrich, S., Keusch, S., Hildenbrand, F. F., Lo Cascio, C., Huber, L. C., Tanner,
F. C., et al. (2015). Effect of nocturnal oxygen and acetazolamide on exercise
performance in patients with pre-capillary pulmonary hypertension and sleep-
disturbed breathing: randomized, double-blind, cross-over trial. Eur. Heart J.
36, 615–623. doi: 10.1093/eurheartj/eht540
Viales, R. R., Eichstaedt, C. A., Ehlken, N., Fischer, C., Lichtblau, M., Grunig, E.,
et al. (2015). Mutation in BMPR2 promoter: a ‘second hit’ for manifestation of
pulmonary arterial hypertension? PLoS One 10:e0133042. doi: 10.1371/journal.
pone.0133042
White, K., Loscalzo, J., and Chan, S. Y. (2012). Holding our breath: The emerging
and anticipated roles of microRNA in pulmonary hypertension. Pulm. Circ. 2,
278–290. doi: 10.4103/2045-8932.101395
Yang, S., Banerjee, S., Freitas, A., Cui, H., Xie, N., Abraham, E., et al. (2012). miR-
21 regulates chronic hypoxia-induced pulmonary vascular remodeling. Am. J.
Physiol. Lung Cell. Mol. Physiol. 302, L521–L529. doi: 10.1152/ajplung.00316.
2011
Yu, D., dos Santos, C. O., Zhao, G., Jiang, J., Amigo, J. D., Khandros, E., et al. (2010).
miR-451 protects against erythroid oxidant stress by repressing 14-3-3zeta.
Genes Dev. 24, 1620–1633. doi: 10.1101/gad.1942110
Zhao, H., Wen, G., Huang, Y., Yu, X., Chen, Q., Afzal, T. A., et al. (2015).
MicroRNA-22 regulates smooth muscle cell differentiation from stem cells by
targeting methyl CpG-binding protein 2. Arterioscler. Thromb. Vasc. Biol. 35,
918–929. doi: 10.1161/ATVBAHA.114.305212
Conflict of Interest Statement: GG and SP are the co-founders of Mirna Analytics.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2018 Grunig, Eichstaedt, Verweyen, Durmus, Saxer, Krafsur, Stenmark,
Ulrich, Grünig and Pylawka. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution
or reproduction in other forums is permitted, provided the original author(s) and
the copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Physiology | www.frontiersin.org 13 July 2018 | Volume 9 | Article 955
